↓ Skip to main content

600- vs 400-mg First-Line Ribociclib in Hormone Receptor–Positive/ERBB2-Negative Advanced Breast Cancer

Overview of attention for article published in JAMA Oncology, November 2025
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

news
2 news outlets
twitter
90 X users
guideline
1 clinical guideline source
bluesky
3 Bluesky users

Readers on

mendeley
13 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
600- vs 400-mg First-Line Ribociclib in Hormone Receptor–Positive/ERBB2-Negative Advanced Breast Cancer
Published in
JAMA Oncology, November 2025
DOI 10.1001/jamaoncol.2025.3687
Pubmed ID
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 90 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 13 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 3 23%
Student > Doctoral Student 1 8%
Lecturer 1 8%
Student > Bachelor 1 8%
Student > Ph. D. Student 1 8%
Other 0 0%
Unknown 6 46%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 4 31%
Pharmacology, Toxicology and Pharmaceutical Science 1 8%
Nursing and Health Professions 1 8%
Sports and Recreations 1 8%
Engineering 1 8%
Other 0 0%
Unknown 5 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 66. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 February 2026.
All research outputs
#826,734
of 34,492,055 outputs
Outputs from JAMA Oncology
#1,189
of 3,969 outputs
Outputs of similar age
#8,001
of 384,557 outputs
Outputs of similar age from JAMA Oncology
#15
of 65 outputs
Altmetric has tracked 34,492,055 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,969 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 83.6. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 384,557 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 65 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.